Tilt Biotherapeutics, A Clinical-Stage Biotechnology Company Developing Cancer Immunotherapies, Has Signed A Second Clinical Trial Collaboration And Supply Agreement With Msd, A Tradename Of Merck & Co., Inc., Rahway, Nj, Usa, For A New Clinical Trial Evaluating Tilt-123, Its Oncolytic Adenovirus Armed With Two Human Cytokines, In Combination With Keytruda (Pembrolizumab), Msd
